LEGEND
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment Nature and Objective:This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of EG-70, a novel non-viral gene therapy, administered intravesically […]
Study 22143
A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC) Nature and ObjectiveThis Phase 1, first-in-human study investigates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of actinium-225-macropa-pelgifatamab (BAY3546828) in individuals with advanced metastatic castration-resistant […]
OMAHA-004
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004) Nature and Objective:This Phase 3 study evaluates the efficacy and safety of opevesostat (MK-5684), a CYP11A1 inhibitor, combined […]
MK-5684-01A Substudy
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Nature and Objective:MK-5684-01A substudy aims to evaluate the safety, tolerability, and preliminary efficacy of opevesostat (MK-5684), a CYP11A1 inhibitor, administered alone or in […]
MEVPRO-1
A Phase 3, Randomized, Open-Label Study Of Pf-06821497 (Mevrometostat) In Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel In Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (MEVPRO-1) Nature and Objective:The MEVPRO-1 study investigates the efficacy of mevrometostat (PF-06821497), an oral inhibitor of EZH2, in combination with enzalutamide, in patients with […]
MEVPRO-2
A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (mevrometostat) with Enzalutamide in Metastatic Castration Resistant Prostate Cancer (MEVPRO-2) Nature and Objective:This Phase I/II open-label, multi-center trial aims to evaluate the safety, tolerability, and anti-tumor activity of [225Ac]Ac-PSMA-R2—a targeted radioligand therapy—in adult men with PSMA-positive metastatic prostate cancer. The study includes patients with […]
SatisfACtion
SatisfACtion: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy. Nature et Objectif:This Phase I/II open-label, multi-center trial aims to evaluate the safety, tolerability, and anti-tumor activity of [225Ac]Ac-PSMA-R2—a targeted radioligand therapy—in adult men with PSMA-positive metastatic prostate cancer. The study includes […]
TACT-Safety
The Effect of Tranexamic Acid on Oncologic Outcomes: The TACT-SAFETY study – Retrospective study Nature et objective :We hypothesize that TXA during cancer surgery is safe and does not increase the risk of cancer recurrence. To address this hypothesis, we aim to extend the follow up of TACT patients beyond the peri-operative period to assess the […]
Pilot project exercise (UQAM)
Optimizing exercise prescription for prostate cancer patients: a pilot study based on participant preferences Nature et objective :A challenge for health professionals is to find adjuvant therapies with a low level of toxicity to combine with standard treatments in order to alleviate the burden of treatment in patients with prostate cancer. Physical activity (PA) is interesting, […]
V940-005
Phase 2, Randomized, Double-blind, Placebo- and Active-comparator controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcinoma Post-radical Resection Nature and objective :The purpose of this study is to assess the safety and efficacy of V940 in combination with pembrolizumab (MK-3475) compared to pembrolizumab alone […]